Viridian Therapeutics Statistics
Viridian Therapeutics (1S1) Stock Statistics & Valuation Metrics
Total Valuation
Viridian Therapeutics has a market cap or net worth of EUR 3.16B. The enterprise value is EUR 1.72B.
- Market Cap
- EUR 3.16B
- Enterprise Value
- EUR 1.72B
Share Statistics
Viridian Therapeutics has 113,558,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 113,558,450
- Owned by Insiders
- 4.57%
- Owned by Institutions
- 46.33%
Financial Efficiency
Viridian Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.81%.
- Return on Equity (ROE)
- -0.47
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -43.81%
- Return on Capital Employed (ROCE)
- -0.44
- Revenue Per Employee
- 281.15K
- Profits Per Employee
- -1.36M
- Employee Count
- 252
- Asset Turnover
- 0.08
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Viridian Therapeutics is -8.07. Viridian Therapeutics’s PEG ratio is 0.44.
- PE Ratio
- -8.07
- PS Ratio
- 134.88
- PB Ratio
- 6.10
- Price to FCF
- -10.33
- Price to Operating Cash Flow
- -10.38
- PEG Ratio
- 0.44
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 70.85M and earned -342.60M in profits. Earnings per share was -3.32.
- Revenue
- 70.85M
- Gross Profit
- 70.85M
- Operating Income
- -363.39M
- Pretax Income
- -342.60M
- Net Income
- -342.60M
- EBITDA
- -337.19M
- Earnings Per Share (EPS)
- -3.32
Cash Flow
In the last 12 months, operating cash flow was -341.50M and capital expenditures -1.94M, giving a free cash flow of -343.44M billion.
- Operating Cash Flow
- -341.50M
- Free Cash Flow
- -343.44M
- Free Cash Flow per Share
- -3.03
Dividends & Yields
Viridian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.68%
- Earnings Yield
- -12.80%
Stock Price Statistics
- Beta
- -0.05
- 52-Week Price Change
- 13.38%
- 50-Day Moving Average
- 19.15
- 200-Day Moving Average
- 18.28
- Relative Strength Index (RSI)
- 77.98
- Average Volume (3m)
- 130
Important Dates
Viridian Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Viridian Therapeutics as a current ratio of 12.65, with Debt / Equity ratio of 7.02%
- Current Ratio
- 12.65
- Quick Ratio
- 12.65
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.48
- Interest Coverage Ratio
- -73.44
Taxes
In the past 12 months, Viridian Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Viridian Therapeutics EV to EBITDA ratio is -8.32, with an EV/FCF ratio of -10.54.
- EV to Sales
- 137.56
- EV to EBITDA
- -8.32
- EV to Free Cash Flow
- -10.54
- EV to Operating Cash Flow
- -10.60
Balance Sheet
Viridian Therapeutics has EUR 955.21M in cash and marketable securities with EUR 243.27M in debt, giving a net cash position of EUR 711.94M billion.
- Cash & Marketable Securities
- EUR 955.21M
- Total Debt
- EUR 243.27M
- Net Cash
- EUR 711.94M
- Net Cash Per Share
- EUR 6.27
- Tangible Book Value Per Share
- EUR 5.03
Margins
Gross margin is 92.98%, with operating margin of -1781.38%, and net profit margin of -1724.06%.
- Gross Margin
- 92.98%
- Operating Margin
- -1781.38%
- Pretax Margin
- -1724.06%
- Net Profit Margin
- -1724.06%
- EBITDA Margin
- -1652.55%
- EBIT Margin
- -1655.22%
Analyst Forecast
The average price target for Viridian Therapeutics is EUR 37.32, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 37.32
- Price Target Upside
- 40.32% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- -62.27%
- EPS Growth Forecast
- -11.52%
Scores
- Smart Score
- 10
- AI Score
- ―
